Perimenopause and Hormone Therapy: Separating Fact from Fear

In July 2002, the Women's Health Initiative (WHI) trial was halted early, and the headlines wrote themselves: hormone therapy causes breast cancer and heart disease. Prescriptions fell off a cliff — by some estimates 80% within a few years. A generation of women went through menopause with their most effective treatment option effectively off the table, and a generation of physicians trained without learning to use it.

Two decades of reanalysis have substantially rewritten that story. It's worth understanding what actually happened.

The WHI enrolled women with an average age of 63 — many more than a decade past menopause — and tested one specific regimen: oral conjugated equine estrogens with a synthetic progestin. The alarming relative risks reported in headlines translated to small absolute risks, and crucially, they described older women starting one particular oral formulation late.

Subsequent analyses revealed what's now called the "timing hypothesis": women who started hormone therapy within 10 years of menopause showed neutral or favorable cardiovascular outcomes and lower all-cause mortality. In the estrogen-only arm (women with prior hysterectomy), breast cancer incidence was actually lower than placebo over long-term follow-up.

Perimenopause — the years of hormonal fluctuation before the final period — can begin in the early 40s and last four to ten years. Symptoms extend far beyond hot flashes: sleep disruption, mood changes, anxiety, brain fog, joint pain, palpitations, and changes in cycle and libido. Because hormone levels swing rather than simply decline, a single blood test can look "normal" while the lived experience is anything but.

Many women are offered antidepressants, sleep aids, or reassurance — treatments aimed at individual symptoms rather than the underlying transition. Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms, and it meaningfully improves sleep and quality of life for many women. It also prevents the rapid bone loss that accelerates at menopause.

Current guidance from The Menopause Society reflects the updated evidence: for healthy women under 60 or within 10 years of menopause onset who have bothersome symptoms, the benefits of hormone therapy generally outweigh the risks. Modern practice also differs from the WHI regimen in ways that matter:

Hormone therapy is not appropriate for everyone — history of breast cancer, clotting disorders, and cardiovascular disease change the calculus, and the decision belongs in a detailed conversation with a licensed clinician who knows your full history.

What the last twenty years have made clear is that the conversation itself was owed to millions of women who never got one. If your symptoms are being dismissed as "just aging," you deserve a provider who will actually review the evidence with you.